Viridian Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Viridian Therapeutics (Nasdaq: VRDN) announced that Jonathan Violin, Ph.D., its President and CEO, will present a company overview at the Oppenheimer Rare & Orphan Disease Summit on May 21 at 9:05 a.m. ET. He will also participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1 at 11:30 a.m. ET. Both events will be accessible via webcasts on Viridian's website, with replays available for 90 days post-event. Viridian focuses on developing treatments for serious diseases, notably its anti-IGF-1R monoclonal antibody, VRDN-001, targeting Thyroid Eye Disease.

BOULDER, Colo., May 14, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the virtual Oppenheimer Rare & Orphan Disease Summit and participate in a fireside chat at the Jefferies Virtual Healthcare Conference.

Event:	Oppenheimer Rare & Orphan Disease Summit
Date:	Friday, May 21ST
Presentation Time:	9:05 a.m. ET
Event:	Jefferies Virtual Healthcare Conference
Date:	Tuesday, June 1ST
Fireside Chat Time:	11:30 a.m. ET

Webcast information for these events will be accessible on the Events page under the Investors section of the Viridian Therapeutics website at www.viridiantherapeutics.com. A replay of both the presentation and fireside chat will be archived on the website and available for approximately 90 days following each live event.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for TED, a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles, and eyelids. Viridian is based in Boulder, Colorado, and Waltham, Massachusetts. Learn more about Viridian and its programs at https://www.viridiantherapeutics.com/.

Follow us on Twitter @ViridianThera and on LinkedIn.

Viridian Contacts:
Investors:
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com

Media:
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com

FAQ

What is the date and time of Viridian Therapeutics' presentation at the Oppenheimer Rare & Orphan Disease Summit?

Viridian Therapeutics will present at the Oppenheimer Rare & Orphan Disease Summit on May 21 at 9:05 a.m. ET.

When will the fireside chat at the Jefferies Virtual Healthcare Conference take place?

The fireside chat at the Jefferies Virtual Healthcare Conference is scheduled for June 1 at 11:30 a.m. ET.

How can I access the webcasts of Viridian Therapeutics' events?

Webcasts for the events will be available on the Events page under the Investors section of the Viridian Therapeutics website.

What is Viridian Therapeutics' lead program VRDN-001 designed to treat?

VRDN-001 is an anti-IGF-1R monoclonal antibody being developed to treat Thyroid Eye Disease (TED).

Where is Viridian Therapeutics located?

Viridian Therapeutics is based in Boulder, Colorado, and Waltham, Massachusetts.